- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma, Pediatric Brain Tumor, Embryonal Tumor With Multilayered Rosettes (ETMR), Pineoblastoma, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, CNS Neuroblastoma, FOXR2-activated
- Interventions
- GPC2-CAR T cells, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 5,720
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7
- Interventions
- Oxaliplatin, Trifluridine and Tipiracil Hydrochloride
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 6
- States / cities
- Elizabeth, New Jersey • Lakewood, New Jersey • Livingston, New Jersey + 3 more
- Conditions
- Relapsed/Refractory Small Cell Lung Cancer
- Interventions
- BMS-986525, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Buffalo, New York • Durham, North Carolina + 2 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Dexamethasone, Rovalpituzumab tesirine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 27
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Fresno, California + 23 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- recombinant human endostatin
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hormone Refractory Prostate Cancer
- Interventions
- AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel
- Drug
- Lead sponsor
- Ascenta Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 24
- States / cities
- Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more
- Conditions
- Head and Neck Neoplasms
- Interventions
- M4N
- Drug
- Lead sponsor
- Erimos Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Advanced Solid Tumors
- Interventions
- TCD-717
- Drug
- Lead sponsor
- Traslational Cancer Drugs Pharma, SL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Detroit, Michigan
- Conditions
- Central Nervous System Lymphoma, Gastric Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Splenic Mantle Cell Lymphoma
- Interventions
- Akt/ERK Inhibitor ONC201, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Alnuctamab, Mezigdomide, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • New York, New York
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Mitoxantrone, Prednisone, Sorafenib
- Drug
- Lead sponsor
- Accelerated Community Oncology Research Network
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 10
- States / cities
- La Verne, California • Atlanta, Georgia • Macon, Georgia + 7 more
- Conditions
- Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell Refractory
- Interventions
- YM155
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Palo Alto, California • Aurora, Colorado + 9 more
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- Daunorubicin
- Drug
- Lead sponsor
- Tara Lin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Fairway, Kansas
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- IMO-8400
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
- Interventions
- Nemtabrutinib, Venetoclax, Rituximab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 6
- States / cities
- Springdale, Arkansas • Long Beach, California • Pembroke Pines, Florida + 3 more
- Conditions
- Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
- Interventions
- Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna, Melphalan, Filgrastim, CliniMACS System
- Drug · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
- Interventions
- EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- Malignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma
- Interventions
- ganetespib, Sirolimus
- Drug
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Washington D.C., District of Columbia • Iowa City, Iowa + 4 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
- Interventions
- LOXO-260
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, cyclophosphamide, melphalan, paclitaxel, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- bryostatin 1, paclitaxel
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Interventions
- Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
- Radiation · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
- Interventions
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
- Biological · Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Melphalan, Mycophenolate Mofetil, Tacrolimus, Thiotepa
- Procedure · Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas